Moreover, in vivo, FPFT-2216 elicited a potent tumor regression effect in combination with the MDM2 inhibitor siremadlin and enhanced the antitumor activity of the anti-human CD20 antibody rituximab. The gene discussed is MDM2; the disease is neoplasm.